Galectin Therapeutics announces preclinical galectin inhibitor data

|About: Galectin Therapeutics, Inc. (GALT)|By:, SA News Editor

Galectin Therapeutics (GALT +3.2%) trades higher after the company says GR-MD-02 and GM-CT-01 demonstrated a "positive therapeutic effect" in NASH with fibrosis.

NASH-induced mice treated with the galectin-inhibitors showed "improved NASH activity and reduced fibrosis including prevention of accumulation of collagen and/or reduced accumulated collagen in the liver."

Data from a first-in-man Phase 1 study of GR-MD-02 is expected early next year. (PR)